Tumor News and Research

RSS

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.

From Novo Nordisk 21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

CMS requested for coverage of two FDG PET scans during the initial treatment

Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission tomography (PET) scans for a patient during the initial treatment evaluation. Currently, CMS covers only one FDG-PET study during initial treatment-a limitation that the groups believe is contrary to good clinical practice under certain circumstances.

20 Oct 2009

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Celsion Corporation announced today that it has received approval from the regulatory agencis in the Philippines and Malaysia for its Pivotal Phase III primary liver cancer Clinical Trial Application.

19 Oct 2009

Yashoda Cancer Institute in India to expand use of Varian Medical Systems' RapidArc radiotherapy

A hospital that is using RapidArc radiotherapy to treat cancers of the head & neck and cervix is announcing it will be expanding its use for treatment of other cancers. Yashoda Cancer Institute in Hyderabad has found it can deliver image-guided, intensity modulated radiotherapy (IMRT) faster and more precisely using the RapidArc technology from Varian Medical Systems.

19 Oct 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

19 Oct 2009

Research study on cowpox virus

In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox.

19 Oct 2009

Rituxan's sBLA receives a Complete Response from the FDA

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.

19 Oct 2009

FDA grants marketing approval for Elitek

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.

19 Oct 2009

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

A study published in the October issue of Nature Genetics demonstrates that loss of the tumor-suppressor protein p53, coupled with elimination of the DNA-maintenance protein ATR, severely disrupts tissue maintenance in mice.

19 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

A set of 87 genes one day may be used to routinely determine which patients can be successfully treated for advanced rectal cancer without undergoing a surgical procedure, researchers announced at the 2009 Clinical Congress of the American College of Surgeons.

15 Oct 2009

Serametrix and the Ludwig Institute for Cancer Research form a partnership

Serametrix Corporation, a personalized medicine company, today announced their partnership with the Ludwig Institute for Cancer Research Ltd. (LICR). The agreement will combine LICR’s historic discoveries in tumor immunology with the technologies and commercial capabilities of Serametrix. This new alliance will enable rapid development and commercialization of tests that predict and monitor drug response in cancer patients. The serum-based tests, which determine immune reaction to tumor antigens, are of value to clinicians and drug developers alike.

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Tumor News and Research

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

ImmunoCellular Therapeutics files a provisional patent application

CMS requested for coverage of two FDG PET scans during the initial treatment

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

FDA approves new oral medication for renal cell carcinoma

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Yashoda Cancer Institute in India to expand use of Varian Medical Systems' RapidArc radiotherapy

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Research study on cowpox virus

Rituxan's sBLA receives a Complete Response from the FDA

FDA grants marketing approval for Elitek

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

Prometheus Laboratories introduces three new cancer diagnostic products

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

Serametrix and the Ludwig Institute for Cancer Research form a partnership

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News